0:00
DR. KATHRIN U. JANSEN: Hello.
My name is Kathrin Jansen.
I'm a Senior Vice President at
Pfizer, responsible for vaccine
research and development.
Today, I will discuss bacterial
vaccines in development.
0:14
Today's lecture is
intended to give you
a brief overview of
licensed bacterial vaccines,
and some examples of bacterial
vaccines in development,
to discuss key principles
of bacterial vaccine design
and development, to share with you
some insights in the R&D efforts
to develop bacterial vaccines.
And I will be using three examples.
The examples I have chosen are
programs that my colleagues
and I are working on at Pfizer.
So they are real life examples
of bacterial vaccine development.
Specifically, we will touch
on vaccines in development
to protect against
toxin-mediated diseases.
The example is
Clostridium difficile.
We will touch on
vaccines in development
to protect against a
very complex organism.
The example is staphylococcus
aureus, where the disease is
mediated by the bacterium
itself, and the virulence
factors that it expresses.
And finally, we will discuss
recently licenced vaccines
to protect the gram-negative
bacterium, Neisseria
meningitidis serogroup B.
